ESR1 and breast cancer: Breast tumors expressing the hormonal receptors are usually luminal A and B breast cancer subtypes which are characterized as a favorable prognosis since they are followed up with hormonal anti-tumor treatments, such as aromatase inhibitors and tamoxifen, which target the estrogen receptor [3].